Bruker at the 5^th Nordic Metabolomics Conference

Meet Bruker at the 5^th Nordic Metabolomics Conference, hosted by the Nordic Metabolomics Society at Uppsala University, Sweden, September 28 - 30, 2026.

Discover Bruker's comprehensive portfolio for metabolomics and lipidomics, combining high-resolution mass spectrometry and advanced NMR technologies to support both targeted quantitation and untargeted discovery workflows. Learn how the latest innovations are helping researchers gain deeper insights into biological systems across pharmaceutical, environmental, and population-scale studies.

• Featured Presentation: "Big Technologies for Small Molecules"
  Join Matthew Lewis as he explores how Bruker's integrated metabolomics and lipidomics portfolio is enabling researchers to uncover deeper biological insights through complementary mass spectrometry and NMR technologies.

The metabolome is dynamic, multidimensional, and endlessly diverse. As one of biology's richest landscapes, the opportunity it brings for discovery is tempered by the analytical challenge that no single technology captures it alone. The choice of analytical platform shapes what we can measure, discover, and ultimately act on within living systems and their environmental interactions.

In this talk, Matthew Lewis (VP, Metabolomics & Lipidomics, Bruker Biosystems) presents Bruker's uniquely complete portfolio across high-resolution mass spectrometry and NMR, from the smallest metabolites to the largest lipoproteins, and the discovery capabilities it enables at speed, depth and scale. He'll show how the timsMetabo™ platform for 4D-Metabolomics™ and 4D-Lipidomics™, increasingly standardised with the biocrates MxQuant hybrid workflow, works hand in hand with the Avance IVDr NMR platform to bring targeted quantitation and untargeted discovery together, meeting the needs of modern clinical and population-scale research.

The session also features recent innovations, including timsMRMS, timsOmni™, and the ecTOF GC-HRMS, together with collaborative insights from Bruker's Nordic partners. There’s a molecular universe out there waiting to be mapped, if you have the right technologies to see it.

Matthew R. Lewis, Ph.D., Vice President Metabolomics & Lipidomics, Bruker Biosystems